|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
EUCTR |
|
Last refreshed on:
|
8 October 2021 |
|
Main ID: |
EUCTR2008-002043-16-ES |
|
Date of registration:
|
17/07/2008 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavir/ritonavir (Kaletra), a emtricitabina/tenofovir disoproxil fumarato (Truvada) más lopinavir/ritonavir (Kaletra) en sujetos adultos infectados con el VIH con colesterol elevado
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of fixed dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kaletra), to Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) Plus Lopinavir/Ritonavir (Kaletra) in Adult HIV-1 Infected Subjects With Raised Cholesterol - ROCKET II- Randomized Open Label Switch for Cholesterol Elevation on Kivexa+Kaletra Evaluation Trial
|
|
Scientific title:
|
Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavir/ritonavir (Kaletra), a emtricitabina/tenofovir disoproxil fumarato (Truvada) más lopinavir/ritonavir (Kaletra) en sujetos adultos infectados con el VIH con colesterol elevado
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of fixed dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kaletra), to Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) Plus Lopinavir/Ritonavir (Kaletra) in Adult HIV-1 Infected Subjects With Raised Cholesterol - ROCKET II- Randomized Open Label Switch for Cholesterol Elevation on Kivexa+Kaletra Evaluation Trial |
|
Date of first enrolment:
|
02/09/2008 |
|
Target sample size:
|
160 |
|
Recruitment status: |
Not Recruiting |
|
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002043-16 |
|
Study type:
|
Interventional clinical trial of medicinal product |
|
Study design:
|
Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
|
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): yes
|
|
|
Countries of recruitment
|
|
Austria
|
Germany
|
Italy
|
Spain
| | | | |
|
Contacts
|
|
Name:
|
|
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
|
|
Name:
|
|
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:
• = 18 years old
• Plasma HIV 1 RNA < 50 copies/mL at Screening and = 12 weeks prior to Screening
• Stable HAART regimen of Kivexa + Kaletra for = 24 weeks prior to Screening
• Documented confirmed raised total cholesterol = 5.2 mmol/L (= 200 mg/dL) for the last two consecutive tests (at least 4 weeks apart) with the last result = 4 weeks prior to Screening
• Fasted total cholesterol = 5.2 mmol/L (= 200 mg/dL) at Screening
• Subject willing to continue current unmodified HAART for 12 weeks if randomized to Group 2
• Subjects requiring concomitant lipid regulating therapy must be established on a stable dose/frequency = 12 weeks prior to Screening and be expected to remain stable in dose and frequency throughout the treatment phase of the study
• Adequate renal function by calculated creatinine clearance = 60 mL/min according to the Cockcroft–Gault formula
• Negative serum pregnancy test (females of childbearing potential only i.e., not surgically sterile or at least 2 years post-menopausal)
• Serum Total Bilirubin = 1.5 mg/dL
Women of childbearing potential (WOCBP) must be using a highly effective method of contraception to avoid pregnancy throughout the study and for up to 30 days after the last dose of study drugs in such a manner that the risk of pregnancy is minimized – refer to Section 7.8 for the definition of highly effective method of birth control.
• Female subjects who are postmenopausal for less than 2 years are required to have follicle stimulating hormone (FSH) = 40 mIU/mL. If the FSH is < 40 mIU/mL, the subject must agree to use highly effective method of birth control to participate in the study– refer to Section 7.8 for the definition of highly effective method of birth control.
• Male subjects who are sexually active must be willing to use effective barrier contraception (e.g. condom with spermicide) during heterosexual intercourse from screening through completion of the study and continuing for up to 30 days after the last dose of study drugs
• Life expectancy = 1 year
• The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion criteria:
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
• Pregnant or lactating subjects
• Previous treatment with emtricitabine (FTC), tenofovir DF (TDF) or adefovir dipivoxil (ADV)
• Known hypersensitivity to emtricitabine (FTC), tenofovir DF (TDF), Truvada or any of the excipients (e.g., lactose monohydrate, see 5.2.1)
• Documented resistance to any of the study drugs (either genotypic or phenotypic)
• Severe hepatic impairment
• Hepatitis B infection with viral load > 1.000 copies/ml at Screening or Hepatitis C infection requiring therapy.
• Treatment with any interferon or pegylated interferon within 18 months prior to Screening.
• Hepatic transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) = 5 × upper limit of normal (ULN)
• Subjects receiving ongoing therapy with any of the medications that are contraindicated with any of the study drugs. Administration of any of these medications must be discontinued at least 30 days prior to the Baseline visit and for the duration of the study period. The full list of disallowed medications can be found in Appendix 5 of the protocol.
• Active, serious infections (other than HIV infection) requiring parenteral antibiotic therapy within 15 days prior to screening
• Prior history of significant renal or bone disease
• Any current known clinical or symptomatic laboratory parameter of GSI Grade 4 (see Appendix 4). Asymptomatic Grade 4 abnormalities will be permitted at the discretion of the investigator if deemed clinically appropriate (excluding adverse events and laboratory parameters mentioned elsewhere in the inclusion/exclusion criteria). Abnormalities deemed insignificant by the investigator must be discussed with the Medical Monitor prior to enrollment.
• Malignancy other than cutaneous Kaposi sarcoma (KS) or basal cell carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of baseline and are not anticipated to require systemic therapy during the study
• Current alcohol or substance use judged by the investigator to potentially interfere with subject study compliance
• Subjects currently taking part in any other clinical trial using an investigational product, with the exception of studies where the treatment studied has been stopped for more than 1 month prior to baseline
• Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements.
Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
|
|
Health Condition(s) or Problem(s) studied
|
Sujetos adultos, infectados con el VIH-1, que están siendo tratados con un régimen TARGA estable de Kivexa + Kaletra, con colesterol elevado.
Adult HIV-1 infected subjects on a stable HAART regimen of Kivexa + Kaletra, with raised cholesterol
MedDRA version: 9.1
Level: LLT
Classification code 10020192
Term: HIV-1
|
|
Intervention(s)
|
Trade Name: TRUVADA
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: emtricitabine
CAS Number: 143491-57-0
Current Sponsor code: FTC
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
INN or Proposed INN: tenofovir disoproxil fumarate
CAS Number: 52232-67-4
Current Sponsor code: TDF
Other descriptive name: tenofovir DF
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
Trade Name: Kivexa
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: abacavir
CAS Number: 136470-78-5
Current Sponsor code: ABC
Other descriptive name: abacavir sulfate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 600-
INN or Proposed INN: lamivudine
CAS Number: 134678-17-4
Current Sponsor code: 3TC
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
Trade Name: Kaletra
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Lopinavir
CAS Number: 192725-17-0
Current Sponsor code: LPV
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
INN or Proposed INN: Ritonavir
CAS Number: 155213-67-5
Current Sponsor code: RTV
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
|
|
Primary Outcome(s)
|
Secondary Objective: • Evaluation of fasting metabolic parameters (e.g., LDL, HDL, non-HDL cholesterol, triglycerides, and cholesterol ratios).
• Evaluation of efficacy and safety by assessing adverse events, clinical laboratory tests, physical examinations and vital signs at every visit.
• Evaluation of changes in the 10-year risk factor for coronary heart disease outcomes as measured by total cholesterol, HDL, blood pressure, smoking status, treatment for hypertension, sex and age.
|
|
Primary end point(s): The primary efficacy endpoint is change from baseline in total cholesterol at Week 12.
|
|
Main Objective: To determine if switching the NRTI backbone from a Kivexa to Truvada leads to a reduction in fasting total cholesterol at 12 weeks.
|
|
Secondary ID(s)
|
|
GS-EU-164-0206
|
|
Source(s) of Monetary Support
|
|
Ethics review
|
Status: Approved
Approval date: 08/08/2008
Contact:
|
|